GHRP-6

Human clinical Growth Hormone In 1 protocol 3 sources

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that stimulates the release of endogenous growth hormone from the pituitary gland. Research shows it can increase appetite, promote muscle growth, and aid in fat loss by mimicking the action of ghrelin.

01Dosing reference

Amount

100-300 mcg per injection

Frequency

1-3 times daily (often fasting or post-workout)

Cycle

8-12 weeks on, followed by a break

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

Receptor Binding

Binds to the ghrelin/growth hormone secretagogue receptor (GHS-R1a) in the pituitary and hypothalamus.

Hormone Secretion

Stimulates a pulsatile release of growth hormone (GH) and subsequently increases insulin-like growth factor 1 (IGF-1) levels.

Systemic Effects

Promotes tissue repair, muscle growth, and intensely stimulates appetite due to its ghrelin-mimicking properties.

03Human evidence

Significant increases in serum growth hormone and IGF-1 levels.

Observed in healthy adults and GH-deficient patients during clinical trials evaluating GH secretagogues.

Marked increase in appetite and food intake shortly after administration.

Noted in observational and controlled studies assessing metabolic and behavioral responses.

04Preclinical evidence

Enhanced muscle recovery and reduced body fat.

Demonstrated in rodent studies assessing body composition changes and metabolic rate.

Cardioprotective effects, including reduced infarct size following ischemia-reperfusion injury.

Observed in porcine and rodent models of myocardial infarction.

05What is known vs. unknown

Reasonably established

Potent stimulator of natural growth hormone release.
Strongly increases appetite, often referred to as the 'gastric emptying' effect.
Can improve sleep quality and enhance recovery from exercise.
Often used in conjunction with GHRH analogs (like CJC-1295) for synergistic effects.

Unknowns & limits

Long-term safety of sustained elevated GH and IGF-1 levels via secretagogues is not fully established.
Potential for desensitization or receptor downregulation with continuous, high-frequency use.
Effects on insulin sensitivity over prolonged periods require more comprehensive study.

06Safety & regulatory context

Regulatory statusGHRP-6 is generally well-tolerated in research settings, with common side effects including intense hunger, water retention, mild lethargy, and occasional injection site reactions. At higher doses, it may elevate cortisol and prolactin levels. It is not FDA-approved for human use and is classified as an investigational chemical. Furthermore, it is banned by WADA and most major sports organizations.

07Compared with Ipamorelin

GHRP-6 vs. Ipamorelin

Key difference

GHRP-6 causes a significant increase in appetite and can elevate cortisol and prolactin at higher doses, whereas Ipamorelin does not significantly affect appetite, cortisol, or prolactin.

When researchers discuss each

GHRP-6 is often discussed when appetite stimulation is desired alongside GH release (e.g., for bulking or cachexia), while Ipamorelin is preferred for a 'cleaner' side-effect profile without hunger.

08Appears in protocols

💪 Growth Hormone Optimization Protocol

100 mcg (optional AM dose)Daily (morning, optional)

09Glossary

Ghrelin

A hormone produced primarily in the stomach that stimulates appetite, increases food intake, and promotes fat storage.

Secretagogue

A substance that causes another substance (such as a hormone) to be secreted or released.

Pulsatile release

The secretion of hormones in bursts or pulses rather than a continuous, steady stream.

10Knowledge check

Q1What is a primary side effect of GHRP-6 that distinguishes it from some other GH secretagogues like Ipamorelin?

Q2Which receptor does GHRP-6 primarily bind to in order to stimulate growth hormone release?

Q3Which of the following is a documented limitation or area needing more research about GHRP-6 in the supplied dossier?

Q4According to the dossier's stated comparison with Ipamorelin, in which research context is GHRP-6 more likely to be discussed or chosen?

Q5Which statement accurately reflects the safety and regulatory context for GHRP-6 as described in the dossier?

11Sources

More in Growth Hormone

See all

Sermorelin

Growth Hormone

FDA-approved context

Sermorelin is a synthetic peptide consisting of the first 29 amino acids of naturally occurring growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to naturally produce and release human growth hormone (hGH), making it a subject of research for age-related growth hormone decline, body composition, and vitality.

200-500 mcg/day

Tesamorelin

Growth Hormone

FDA-approved context

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to secrete growth hormone. It is FDA-approved for reducing excess visceral abdominal fat in HIV-infected patients with lipodystrophy and is being researched for potential cognitive benefits.

2 mg/day

Hexarelin

Growth Hormone

Human clinical

Hexarelin is a potent, synthetic hexapeptide and growth hormone secretagogue (GHS) that stimulates the release of growth hormone. Research indicates it is one of the strongest GH-releasing peptides available, offering potential benefits for muscle growth, fat loss, and cardiovascular health without significantly increasing appetite.

100-200 mcg per dose

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.